Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Amer F. Saleh"'
Autor:
Wooi F. Lim, Melissa Bowerman, Corinne A. Betts, Lara Cravo, Aarti Jagannath, Tirsa L.E. van Westering, Jinhong Meng, Katarzyna Chwalenia, Russell G. Foster, Jennifer E. Morgan, Carlo Rinaldi, Maria Sofia Falzarano, Elizabeth O’Donovan, Alessandra Ferlini, Graham McClorey, Katharina E. Meijboom, John R. Counsell, Amarjit Bhomra, Matthew J.A. Wood, Michael J. Gait, Amer F. Saleh, Subhashis Banerjee
Publikováno v:
Life Science Alliance
Absence of integral sarcolemmal protein, dystrophin, disrupts the RhoA-actin-SRF cascade in skeletal muscle, with subsequent dysregulation of downstream-SRF circadian targets and circadian rhythm.
Absence of dystrophin, an essential sarcolemmal
Absence of dystrophin, an essential sarcolemmal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d711e18ebfc93027b1f5621297a5949
https://doi.org/10.26508/lsa.202101014
https://doi.org/10.26508/lsa.202101014
Autor:
Amer F. Saleh, Janusz Rak, Elisa Lázaro-Ibáñez, Khuloud T. Al-Jamal, Farid N. Faruqu, Niek Dekker, Julie Tzu-Wen Wang, Andreia M. Silva
Publikováno v:
ACS Nano
The ability to track extracellular vesicles (EVs) in vivo without influencing their biodistribution is a key requirement for their successful development as drug delivery vehicles and therapeutic agents. Here, we evaluated the effect of five differen
Autor:
Alberto Malerba, Jagjeet K Kang, Graham McClorey, Amer F Saleh, Linda Popplewell, Michael J Gait, Matthew JA Wood, George Dickson
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 1, Iss C (2012)
The knockdown of myostatin, a negative regulator of skeletal muscle mass may have important implications in disease conditions accompanied by muscle mass loss like cancer, HIV/AIDS, sarcopenia, muscle atrophy, and Duchenne muscular dystrophy (DMD). I
Externí odkaz:
https://doaj.org/article/58a7f59b4ffc4b1299392e488bfee511
Autor:
Corinne Betts, Amer F Saleh, Andrey A Arzumanov, Suzan M Hammond, Caroline Godfrey, Thibault Coursindel, Michael J Gait, Matthew JA Wood
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 1, Iss C (2012)
Antisense oligonucleotides (AOs) are currently the most promising therapeutic intervention for Duchenne muscular dystrophy (DMD). AOs modulate dystrophin pre-mRNA splicing, thereby specifically restoring the dystrophin reading frame and generating a
Externí odkaz:
https://doaj.org/article/bbb94f06c18043ce89b202330292cdea
Autor:
Olga Shatnyeva, Emilyanne Leonard, Xabier Osteikoetxea, Mick D. Fellows, Amer F. Saleh, Nicholas Edmunds, Madeleine Ingelsten, Elisa Lázaro-Ibáñez, Maryam Clausen, Stephanie M. Bates, Niek Dekker, Fredrik Karlsson, Damla Etal, Nikki Heath, Jonathan A. Rose, Jayne Harris, Maelle Mairesse, Malin Forsgard
Publikováno v:
Nanoscale. 11(14)
Extracellular vesicles (EVs) mediate cellular communication through the transfer of active biomolecules, raising interest in using them as biological delivery vehicles for therapeutic drugs. For drug delivery applications, it is important to understa
Autor:
Nicholas Edmunds, Amer F. Saleh, Catherine C. Priestley, Martin Bachman, Patrik U. Andersson, Mick D. Fellows, Nigel J. Gooderham, Scott P. Henry
Publikováno v:
Toxicological sciences : an official journal of the Society of Toxicology. 163(1)
Nucleoside analogs with 2'-modified sugar moieties are often used to improve the RNA target affinity and nuclease resistance of therapeutic oligonucleotides in preclinical and clinical development. Despite their enhanced nuclease resistance, oligonuc
Autor:
Ngoc Lu-Nguyen, Amer F. Saleh, George Dickson, Linda Popplewell, Michael J. Gait, Susan Jarmin
Publikováno v:
Molecular Therapy. 23:1341-1348
The fatal X-linked Duchenne muscular dystrophy (DMD), characterized by progressive muscle wasting and muscle weakness, is caused by mutations within the DMD gene. The use of antisense oligonucleotides (AOs) modulating pre-mRNA splicing to restore the
Autor:
Amer F. Saleh, Ülo Langel, Mattias Hällbrink, Michael J. Gait, Graham McClorey, Samir El Andaloussi, Suzan M. Hammond, Matthew J.A. Wood, C. I. Edvard Smith, Peter Järver, Andrey A. Arzumanov, Eman M. Zaghloul
Publikováno v:
Nucleic Acid Therapeutics
Oligonucleotide analogs have provided novel therapeutics targeting various disorders. However, their poor cellular uptake remains a major obstacle for their clinical development. Negatively charged oligonucleotides, such as 2′-O-Methyl RNA and lock
Publikováno v:
Toxicological Sciences. 145:169-176
Oligonucleotide (OND)-based therapeutics and antisense ONDs in particular, are widely used for modulating gene expression inside cells with promising clinical potential (Graham et al., 2013; Thomas et al., 2013). Various chemical modifications to the
Autor:
Graham McClorey, Michael J. Gait, A. Blain, Corinne A. Betts, Thomas C. Roberts, Raquel Manzano, Hanns Lochmüller, Anna M.L. Coenen-Stass, Matthew J.A. Wood, Amer F. Saleh
Publikováno v:
Scientific Reports
There is currently an urgent need for biomarkers that can be used to monitor the efficacy of experimental therapies for Duchenne Muscular Dystrophy (DMD) in clinical trials. Identification of novel protein biomarkers has been limited due to the massi